Skip to main content
Conference Proceedings

An interim analysis of phase I clinical trial of MCC-465, a doxorubicin (DXR) encapsulated in PEG-immunoliposome, in patients with metastatic stomach cancer

Advances in Experimental Medicine and Biology (2003) 519 179-193
DOI: 10.1007/0-306-47932-x_11
4Citations
Citations of this article
8Readers
Mendeley users who have this article in their library.
Get full text

Cite

CITATION STYLE

APA

Matsumura, Y. (2003). An interim analysis of phase I clinical trial of MCC-465, a doxorubicin (DXR) encapsulated in PEG-immunoliposome, in patients with metastatic stomach cancer. In Advances in Experimental Medicine and Biology (Vol. 519, pp. 179–193). https://doi.org/10.1007/0-306-47932-x_11

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free